Fujiki Jumpei, Yokoyama Daigo, Yamamoto Haruka, Kimura Nana, Shimizu Manaho, Kobayashi Hinatsu, Nakamura Keisuke, Iwano Hidetomo
Department of Veterinary Medicine, Rakuno Gakuen University, Ebetsu 069-8501, Japan.
Phage Therapy Institute, Comprehensive Research Organization, Waseda University, Tokyo 162-8480, Japan.
Viruses. 2025 Aug 4;17(8):1080. doi: 10.3390/v17081080.
Phage therapy, long overshadowed by antibiotics in Western medicine, has a well-established history in some Eastern European countries and is now being revitalized as a promising strategy against antimicrobial resistance (AMR). This resurgence of phage therapy is driven by the urgent need for innovative countermeasures to AMR, which will cause an estimated 10 million deaths annually by 2050. However, the emergence of phage-resistant variants presents challenges similar to AMR, thus necessitating a deeper understanding of phage resistance mechanisms and control strategies. The highest priority must be to prevent the emergence of phage resistance. Although phage cocktails targeting multiple receptors have demonstrated a certain level of phage resistance suppression, they cannot completely suppress resistance in clinical settings. This highlights the need for strategies beyond simple resistance suppression. Notably, recent studies examining fitness trade-offs associated with phage resistance have opened new avenues in phage therapy that offer the potential of restoring antibiotic susceptibility and attenuating pathogen virulence despite phage resistance. Thus, controlling phage resistance may rely on both its suppression and strategic redirection. This review summarizes key concepts in the control of phage resistance and explores evolutionary engineering as a means of optimizing phage therapy, with a particular focus on infections. Harnessing evolutionary dynamics by intentionally breaking the spontaneous evolutionary trajectories of target bacterial pathogens could potentially reshape bacterial adaptation by acquisition of phage resistance, unlocking potential in the application of phage therapy.
噬菌体疗法在西方医学中长期被抗生素掩盖,但在一些东欧国家有着悠久的历史,现在正作为一种对抗抗菌药物耐药性(AMR)的有前景的策略而复兴。噬菌体疗法的这种复兴是由对抗菌药物耐药性采取创新对策的迫切需求推动的,预计到2050年,抗菌药物耐药性每年将导致1000万人死亡。然而,噬菌体抗性变体的出现带来了与抗菌药物耐药性类似的挑战,因此有必要更深入地了解噬菌体抗性机制和控制策略。当务之急必须是防止噬菌体抗性的出现。尽管针对多种受体的噬菌体鸡尾酒已显示出一定程度的噬菌体抗性抑制作用,但它们在临床环境中无法完全抑制抗性。这凸显了除简单的抗性抑制之外的策略的必要性。值得注意的是,最近关于与噬菌体抗性相关的适应性权衡的研究为噬菌体疗法开辟了新途径,尽管存在噬菌体抗性,但仍有可能恢复抗生素敏感性并减弱病原体毒力。因此,控制噬菌体抗性可能既依赖于对其抑制,也依赖于策略性的重新定向。本综述总结了控制噬菌体抗性的关键概念,并探讨了进化工程作为优化噬菌体疗法的一种手段,特别关注感染。通过有意打破目标细菌病原体的自发进化轨迹来利用进化动力学,可能会通过获得噬菌体抗性来重塑细菌适应性,从而释放噬菌体疗法应用中的潜力。